- Adherence among chronic disease patients can lead to big savings
- Laura Geller supports MS awareness with Bring on the Bronze kit
- Sanofi MS drug shows good results in phase-3 trial
- More than one-third of dispensed prescriptions sent electronically in 2011, report finds
- Medication adherence could be blockbuster for specialty
CAMBRIDGE, Mass. — An experimental drug for multiple sclerosis produced a noticeable reduction in symptoms of the disease in a late-stage clinical trial, the drug's developer said Friday.
Genzyme, a unit of French drug maker Sanofi, announced results from a phase-3 study of Aubagio (teriflunomide) in patients with relapsing forms of MS. According to the study, patients taking the drug in the 14-mg strength experienced a 36.3% reduction in annualized relapse rates and 31.5% reduction in the risk of sustained accumulation of disability over a 12-week period.
The study enrolled 1,169 patients who received once-daily doses of Aubagio in the 7-mg or 14-mg strength or placebo. After completing the approximately 18-month trial, patients were followed for 48 to 173 weeks.
In the treatment group that received the 7-mg strength of the drug, there was a 22.3% reduction in annualized relapse rate, but no statistically significant difference between the lower dose and placebo for the risk of 12-week sustained accumulation of disability.